(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
Ringleader of suspected human trafficking network arrested in Ethiopia- Vote in favor of the Web-based Work out schedule to Keep You Fit and Sound
- Defense Minister Katz moves to extend IDF service to 36 months
- 6 Robot Vacuum Cleaners for Easy Home Cleaning
- From Specialist to Proficient Picture taker: Individual Triumphs
- Best Internet based Course for Learning Another Dialect: Which Stage Do You Like?
- Share your pick for the tree that you love for its novel magnificence!
- Huge solar flare no threat to Artemis 2 astronaut launch to the moon, NASA says
- Meet the Stars of the Feline World: Well known Pet Feline Varieties
